

## Bangladesh SUPPORT for INACTIVATED POLIO VACCINE (IPV)

## This Decision Letter sets out the Programme Terms of a Programme.

- 1. Country: Bangladesh
- 2. Grant Number: 1418-BGD-25b-X / 1418-BGD-25b-Y /14-BGD-08h-Y
- 3. Date of Decision Letter: 22 December 2014<sup>1</sup> (replaces the previous Decision Letter for IPV issued on 30 June 2014)
- 4. Date of the Partnership Framework Agreement: 24 June 2013
- 5. Programme Title: NVS, IPV Routine
- 6. Vaccine type: Inactivated Polio Vaccine (IPV)
- 7. Requested product presentation and formulation of vaccine<sup>2</sup>: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID
- 8. Programme Duration<sup>3</sup>: 2015 2018
- 9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):

Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI's review and approval processes.

	2015	2016	Total⁴
Programme Budget (US\$)	US\$ 10,014,000	US\$ 8,845,500	US\$ 18,859,500

**10. Vaccine Introduction Grant:** US\$2,498,000 sent to Bangladesh on 13 August 2014, as per decision letter dated 30 June 2014.

<sup>&</sup>lt;sup>1</sup> This Decision Letter replaces and supplants the Decision Letter dated 30 June 2014 issued to the Country with a 10-dose product presentation. Since that time, WHO has pre-qualified a 5-dose product presentation. As implementation has not started, Gavi is providing the government with the 5-dose product presentation as set out in this Decision Letter.

<sup>&</sup>lt;sup>2</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>&</sup>lt;sup>3</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>4</sup> This is the total amount endorsed by GAVI for 2014 to 2016.



11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): The Annual Amount for 2015 has changed from the previous Decision Letter which was issued on 30 June 2014 and which has now been replaced by this Decision Letter:

Type of supplies to be purchased with	2015
GAVI funds in each year (1418-BGD-25b-X)	
Vaccine Doses	4,892,700
Annual Amounts (US\$)	US\$ 9,785,500

Type of supplies to be purchased with GAVI funds in each year (1418-BGD-25b-Y)	2015
AD Syringes	4,087,300
Re-constitution Syringes	
Safety Boxes	44,975
Annual Amounts (US\$)	US\$ 228,500

- 12. Procurement agency: UNICEF
- 13. Self-procurement: Not applicable
- 14. Co-financing obligations: N/A

GAVI's usual co-financing requirements do not apply to IPV. However, **Bangladesh** is encouraged to contribute to vaccine and/or supply costs for IPV.

- 15. Operational support for campaigns: N/A
- 16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	15 May 2015

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI\*:

Not applicable

\*Failure to provide the financial clarifications requested may result in GAVI withholding further

18. Other conditions: Not applicable.

Signed by, Maryse ) ugui, 050

On behalf of the GAVI Alliance Hind Khatib-Othman

Managing Director, Country Programmes

22 December 2014

<sup>5</sup> This is the amount that GAVI has approved.

2 Chemin des Mines Tel 1202 Geneva. Switzerland Fax

Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50 www.gavi.org info@gavi.org